The largest community of pharma leaders

Geneoscopy Appoints Mark Van Cleve, PhD as Vice President of Product Development

ST. LOUIS–()–Geneoscopy, Inc., a life sciences company focused on the development of diagnostic tests for gastrointestinal (GI) health, today announced it has appointed Mark Van Cleve, PhD as Vice President of Product Development.

“Mark brings a wealth of experience in IVD product development and a proven track record of success,” said Andrew Barnell, CEO of Geneoscopy. “He is the ideal person to lead our product development team.”

Dr. Van Cleve has more than 25 years of experience in the design and development of in vitro diagnostic products and technologies. Most recently, Dr. Van Cleve served as Head of R&D, Clinical Lab Menu at Ortho Clinical Diagnostics, where he oversaw the R&D department responsible for developing new assays, lifecycle management of existing products, and field triage. Previously, Dr. Van Cleve served as Vice President of R&D at Hycor Biomedical. Prior to his tenure at Hycor Biomedical, Dr. Van Cleve held roles at Agilent Technologies, Chiron Corporation, and BD Biosciences. Dr. Van Cleve holds a PhD in Biochemistry from the University of Illinois at Urbana-Champaign and a B.A. in Chemistry from Knox College.

“Geneoscopy is well positioned to leverage its stool-derived eukaryotic RNA extraction platform in a proven market with a demonstrated need for prevention and early detection,” said Dr. Van Cleve. “I am very excited for the opportunity to significantly improve human health as a member of the Geneoscopy team.”

Source

Recent Articles

AVROBIO to Present at Two Upcoming Investor Conferences

CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $AVRO--AVROBIO, Inc. (Nasdaq: AVRO), a leading clinical-stage gene...

Global Neurofibromatosis Treatment Drugs Market to Surpass US$ 21,223.7 Million by 2027, Says Coherent Market Insights (CMI)

SEATTLE--(BUSINESS WIRE)-- #NeurofibromatosisTreatment--The Asia Pacific is expected to witness significant growth...

FDA Approves Nucala as the First and Only Biologic Treatment for Hypereosinophilic Syndrome (HES)

LONDON--(BUSINESS WIRE)--GlaxoSmithKline plc (GSK) (LSE/NYSE: GSK) today announced the US Food...

Novocure Honors Mesothelioma Day with Activities to Raise Awareness of Mesothelioma and Support the Community

ST. HELIER, Jersey--(BUSINESS WIRE)--Novocure announced today initiatives to bring attention to...

Veracyte Receives ADLT Status for Envisia Genomic Classifier From Centers for Medicare and Medicaid Services

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Veracyte Receives ADLT Status for Envisia Genomic...
2020 Call for Writers

Are you looking to inspire others in the pharma industry through your writing? You’re invited to submit your articles to become a Featured Writer for The Pharmaceutical Marketing Group website.